Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658670 | 0.92 | MGLL (0.39) | NAMPTACHEHTR4MGLL | |
| SCHEMBL19658599 | 0.92 | KDM4E (0.40) | NAMPTACHEHTR4KDM4EPOLB | |
| SCHEMBL19652178 | 0.85 | HTR4 (0.39) | NAMPTHTR4MGLLKDM4EUBE2M | |
| SCHEMBL18724551 | 0.83 | NSD2 (0.39) | KDM4EPOLBMAPTKMT2A | |
| SCHEMBL19658671 | 0.81 | ACHE (0.43) | ACHEHTR4 | |
| SCHEMBL19658480 | 0.81 | ACHE (0.47) | ACHEHTR4 | |
| SCHEMBL5988002 | 0.80 | PIK3CD (0.43) | KDM4EPOLBMAPTKMT2A | |
| SCHEMBL19658487 | 0.80 | ACHE (0.50) | ACHEHTR4 | |
| SCHEMBL19652169 | 0.78 | MGLL (0.37) | ACHEHTR4MGLL | |
| SCHEMBL19658666 | 0.77 | KMT2A (0.45) | NAMPTACHEKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | NAMPT 571/4885ACHE 2649/4885HTR4 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.